Angle (AGL)

Sector:

Support

Index:

FTSE AIM All-Share

6.50p
   
  • Change Today:
      0.25p
  • 52 Week High: 16.50p
  • 52 Week Low: 5.00p
  • Currency: UK Pounds
  • Shares Issued: 322.64m
  • Volume: 678,645
  • Market Cap: £20.97m
  • RiskGrade: 312

Deal with Barclays    Trade now with Barclays Stockbrokers

Angle granted European patent for CellKeep, US patent imminent

By Josh White

Date: Monday 22 Apr 2024

LONDON (ShareCast) - (Sharecast News) - Liquid biopsy specialist Angle announced on Monday that it has received a European patent for its 'CellKeep' slide, as it anticipated the imminent grant of an equivalent US patent application.
The AIM-traded firm said the CellKeep slide, developed over three years, addresses the prevalent issue of circulating tumour cell (CTC) loss in standard laboratory microscopy techniques for cytological analysis.

Through in-house testing, the proprietary slide demonstrated an impressive elimination of over 70% of CTC loss associated with conventional techniques.

The board said the breakthrough was significant as it enhanced the efficiency of the 'Parsortix' system, which captures intact and viable CTCs from blood for downstream analysis.

By minimising cell loss during the transfer of CTCs to microscope slides and preserving cell morphology, the CellKeep slide ensured higher sample positivity rates and better preservation of CTC morphology and clusters.

Moreover, the company said the use of CellKeep slides reduced costs by concentrating CTCs into a smaller area on the slide, limiting the quantity of high-cost antibodies and imaging time required for analysis.

Angle said the CellKeep slide was an integral component of its 'Portrait+' CTC staining kit, providing customers with enhanced capabilities to identify and enumerate CTCs harvested using the Parsortix system.

"We are delighted to have secured intellectual property rights for our proprietary CellKeep slide in two major jurisdictions," said chief executive officer Andrew Newland.

"Following harvesting of rare CTCs from patient blood samples using the Parsortix system, the CellKeep slide and associated methodology will significantly improve the capture of CTCs for microscopy-based biomarker assays and will enhance sensitivity across Angle's assay portfolio.

"This is a significant technology advancement for the CTC liquid biopsy field and another step towards enabling biomarker-guided precision medicine for people with cancer."

At 0919 BST, shares in Angle were up 8.33% at 13p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Angle Market Data

Currency UK Pounds
Share Price 6.50p
Change Today 0.25p
% Change 4.00 %
52 Week High 16.50p
52 Week Low 5.00p
Volume 678,645
Shares Issued 322.64m
Market Cap £20.97m
RiskGrade 312

Angle Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
19.42% below the market average19.42% below the market average19.42% below the market average19.42% below the market average19.42% below the market average
36.47% above the sector average36.47% above the sector average36.47% above the sector average36.47% above the sector average36.47% above the sector average
Price Trend
85.01% below the market average85.01% below the market average85.01% below the market average85.01% below the market average85.01% below the market average
87.1% below the sector average87.1% below the sector average87.1% below the sector average87.1% below the sector average87.1% below the sector average
Income Not Available
Growth
54.99% above the market average54.99% above the market average54.99% above the market average54.99% above the market average54.99% above the market average
56.82% above the sector average56.82% above the sector average56.82% above the sector average56.82% above the sector average56.82% above the sector average

What The Brokers Say

Strong Buy 1
Buy 1
Neutral 0
Sell 0
Strong Sell 0
Total 2
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Angle Dividends

No dividends found

Trades for 22-Aug-2025

Time Volume / Share Price
17:05 55,000 @ 6.50p
14:25 10,265 @ 6.78p
14:15 19,019 @ 6.83p
13:37 5,010 @ 6.33p
13:35 235 @ 7.00p

Angle Key Personnel

CEO Andrew D Newland
Finance Director Ian F Griffiths
Chair Jan Groen

Top of Page